Efficacy And Safety Of Low-dose Gemcitabine Combined With Nedaplatin In The Treatment Of Elderly Patients With Advanced Urothelial Carcinoma

Objective To observe the efficacy and safety of low-dose gemcitabine combined with nedaplatin in the treatment of elderly patients with advanced urothelial carcinoma.Methods A retrospective analysis was performed on the efficacy and adverse reactions of 42elderly patients with advanced urothelial carcinoma aged 70 years and above who received low-dose gemcitabine combined with nedaplatin in the Department of Oncology,Wuhan Central Hospital from January 2015 to January 2018.The specific chemotherapy regimen was that low-dose gemcitabine 800 mg/m~2was given intravenously on the 1st and 8th day of the first chemotherapy cycle,and nedaplatin total 70 mg/m~2was given on the 2nd-4th day.The chemotherapy regimen was repeated in the next chemotherapy cycle,with 21 days as a chemotherapy cycle.Results Among the 42 patients,0 had complete remission,11 had partial remission(26.19%),16 had stable disease(38.10%),and 15 had progressive disease(35.71%).The objective remission rate was 26.19%,the disease control rate was 64.29%,and the The median progression-free survival time was 5.1 months,and the median overall survival time was 9.6months.The main adverse reactions were leukopenia(42.86%),thrombocytopenia(38.10%),anemia(45.24%),nausea(38.10%),vomiting(28.57%),abnormal liver function(9.52%),abnormal renal function(4.76%),the incidence of gradeⅢ-Ⅳadverse reactions was 9.52%,and there was no treatment-related death.After treatment,the levels of cytokeratin 19fragment(CYFRA21-1),squamous cell carcinoma(SCC-Ag)were lower than those before treatment,and the difference was statistically significant(P<0.05).Conclusion The low-dose gemcitabine combined with nedaplatin regimen is effective and safe in the treatment of elderly patients with advanced urothelial carcinoma.